Mesenchymal Stromal Cells in Solid Organ Transplantation

Area of Science:

• Regenerative Medicine
• Immunology
• Transplantation Science

Background:

• Mesenchymal stromal cells (MSCs) are increasingly explored for cell-based therapies in solid organ transplantation (SOT).
• Extensive research highlights MSCs' anti-inflammatory, immunomodulatory, and tissue-repair capabilities.
• Preclinical successes have paved the way for clinical trials investigating MSCs in SOT.

Purpose of the Study:

• To review the fundamental properties of MSCs, focusing on their immune system interactions and role in ischemic conditioning.
• To provide a chronological overview of all conducted clinical trials involving MSCs in SOT.
• To discuss the future challenges and prospects of MSC-based cell therapy within the SOT field.

Main Methods:

• Literature review of experimental studies on MSC properties.
• Systematic compilation and chronological analysis of clinical trials in SOT using MSCs.
• Synthesis of current data to project future directions for MSC therapy in transplantation.

Main Results:

• MSCs possess significant immunomodulatory and tissue-regenerative potential relevant to transplantation.
• A growing number of clinical trials have evaluated MSC therapy across various SOT contexts.
• Early-phase trials suggest potential benefits, though efficacy and optimal protocols require further investigation.

Conclusions:

• MSCs represent a promising therapeutic avenue for improving outcomes in solid organ transplantation.
• Further research and well-designed clinical trials are essential to overcome challenges and realize the full potential of MSC therapy in SOT.
• The future of MSCs in SOT hinges on refining delivery methods, understanding mechanisms, and demonstrating long-term safety and efficacy.